Evidence map›Paper›PMID 35643857›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2022

Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.

David R Maguire, Charles P France

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David R MaguireDepartment of Pharmacology, (D.R.M., C.P.F.), Addiction Research, Treatment & Training Center of Excellence (D.R.M., C.P.F.), and Department of Psychiatry (C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Charles P FranceDepartment of Pharmacology, (D.R.M., C.P.F.), Addiction Research, Treatment & Training Center of Excellence (D.R.M., C.P.F.), and Department of Psychiatry (C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas france@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · US

Funding

A novel opioid receptor antagonist for treating abuse and overdoseR01DA048417 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FRANCE, CHARLES P · 2019 to 2023
$2.6M
NIDA NIH HHS R01 DA048417
6 · The paper itself

Abstract

Methocinnamox (MCAM), a long-acting

Indexed as

CinnamatesMorphine DerivativesOpioid-Related DisordersAnalgesics, OpioidAnimalsCocaineDose-Response Relationship, DrugFemaleFentanylMacaca mulattaMaleNaltrexoneNarcotic AntagonistsReceptors, Opioid, muSelf AdministrationAnalgesics, OpioidCinnamatesCocaineFentanylmethocinnamoxMorphine DerivativesNaltrexoneNarcotic AntagonistsReceptors, Opioid, mu

Identifiers

PMID35643857
PMCPMC9341267
OpenAlexW4281758394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.